During this study an update of the data from the 2017 Cochrane Review “Selective progesterone receptor modulators (SPRMs) for uterine fibroids”, was conducted by a systematic search of Pubmed and trial and review registers, using the terms “ulipristal” and “fibroid” (Oct 1, 2022), which did not identify any additional published direct or network comparisons of selective progesterone receptor modulators. This evidence concerns the gene PGR and uterine corpus leiomyoma.